|
|
Cationic liposome-DNA complex JVRS-100 |
|
Vaxjo ID |
2 |
|
Vaccine Adjuvant Name |
Cationic liposome-DNA complex JVRS-100 |
|
Alternative Names |
CLDC JVRS-100 |
|
Adjuvant VO ID |
VO_0001339
|
|
Description |
The CLDC are virus-sized particulates, with a mean diameter of ~120 nm, which facilitates trafficking to antigen-presenting cells in lymph nodes draining the site of inoculation. The nature of the enhanced immune responses suggests that vaccines and specifically, recombinant vaccines, would be greatly improved by administration with CLDC as an adjuvant. CLDC-adjuvanted vaccines have previously been shown to produce a greater CD8+ T-cell-specific response than Freund's complete adjuvant, peptide-pulsed dendritic cells, vaccinia vectored, and DNA vaccines (Chang et al., 2009). |
|
Stage of Development |
Clinical Trial |
|
Structure |
DNA plasmid pMB76.5 4242 bases long, plus cationic liposomes, lactose and cholesterol. |
|
Function |
Activation of innate immunity by CLDC is modulated by dose and route of administration, but is not species specific. In multiple species (mouse, rabbit, dog, monkey), CLDC treatment results in an immediate up-regulation of a broad-array of soluble and cellular host defenses such as release of IL-12 and interferons with the accumulation of macrophages and NK cells. In addition to the utility of CLDC in promoting an antiviral response, administration of CLDC is efficacious against tumor progression in mouse models of cancer and in dogs with naturally occurring tumors. The addition of CLDC to antigens has been shown to produce a potent adjuvant effect following subcutaneous or intramuscular vaccination, with induction of enhanced T-cell and antibody responses (Chang et al., 2009). |
| Related Vaccine(s) |
|
| References |
Chang et al., 2009: Chang S, Warner J, Liang L, Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals : journal of the International Association of Biological Standardization. 2009; 37(3); 141-147. [PubMed: 19285425].
|
|
